GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation

ORLANDO, FL, USA ( - Presented by Matthew R. Smith,1 Emmanuel S. Antonarakis,2 Charles J. Ryan,3 William R. Berry,4 Neal Shore,5 Glenn Liu,6 Joshi J. Alumkal,7 Celestia S. Higano,8 Edna Chow Maneval,9 and Dana E. Rathkopf10 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA


1Massachusetts General Hospital and the Harvard Medical School, Boston, MA; 2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; 3UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 4Cancer Centers of North Carolina, Raleigh, NC; 5Carolina Urologic Research Center, Myrtle Beach, SC; 6University of Wisconsin Carbone Cancer Center, Madison, WI; 7Oregon Health & Science University Knight Cancer Institute, Portland, OR; 8Seattle Cancer Care Alliance and the University of Washington, Seattle, WA; 9Aragon Pharmaceuticals, San Diego, CA; 10Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY


Read session highlights by a reporter.


View Full 2013 GU Cancers Symposium Coverage